A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography.

A rapid, sensitive, and accurate ultra-fast liquid chromatographic method is developed for the determination of related substances and degradants of Solifenacin Succinate, an active pharmaceutical ingredient used in the treatment of overactive bladder. Chromatographic separation of Solifenacin Succinate, its related substances, and degradants was achieved using a Shimpack XR-ODS-II column and mobile phase system containing 10 mM potassium dihydrogen orthophosphate in water. The pH of the buffer was adjusted to 7.0 using triethyl amine (mobile phase A). LC-grade acetonitrile was used as mobile phase B, employing a binary-gradient program at a flow rate 0.5 mL/min. The resolution between the critical pair of peaks (Impurity A and analyte) was found to be greater than 3.5. The limits of detection and quantification (LOQ) of Impurity A, Impurity B, and the analyte were 0.2 and 0.6 µg/mL, respectively for a 5-µL injection volume. The percentage recovery of impurities in the presence of sample matrix ranged from 95 to 104 w/w. The test solution and mobile phase was observed to be stable up to 24 h after the preparation. The validated method yielded good results of precision, linearity, accuracy, robustness, and ruggedness. The proposed method is found to be rapid, accurate, and suitable for the quantitative determination of related substances and degradants during quality control of Solifenacin Succinate active pharmaceutical ingredient.

Identification, isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance.

During stress degradation studies of pioglitazone hydrochloride, one major unknown oxidative degradation impurity and two major unknown base degradation impurities were identified by LC-MS. These impurities were isolated using preparative liquid chromatography. Based on the spectral data (1H NMR, 13C NMR, MS and IR), oxidative degradation impurity, base degradation impurity-1 and base degradation impurity-2 were characterized as pioglitazone N-oxide, 3-(4-(2-(5-ethylpyridine-2yl) ethoxy) phenyl)-2-mercaptopropanoic acid and 2-(1-carboxy-2-{4-[2-(5-ethylpyridine-2yl)-ethoxy] phenyl}-ethyl disulfanyl)-3-{4-[2-(5-ethylpyridine-2yl)-ethoxy] phenyl propanoicacid, respectively. The formation and mechanism of these impurities were discussed and presented.

Development and validation of a high performance liquid chromatographic method for the separation of exo and endo isomers of granatamine (9-methyl-9-azabicyclo[3.3.1]nonan-3-amine); a key intermediate of granisetron.

A simple and accurate high-performance liquid chromatographic method was developed for the determination of exo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine in endo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine, commercially known as grantamine and used as a key intermediate in the preparation of granisetron bulk drug. Chromatographic separation of the exo and endo isomers of 9-methyl-9-azabicyclo[3.3.1]nonan-3-amine was achieved on an Inertsil C8 column using a mobile phase containing 0.3% trifluoroacetic acid. The resolution between the two isomers was found to be more than 4. The limit of detection (LOD) and limit of quantification (LOQ) of exo isomer were 0.8 and 2.5 microg x mL(-1) respectively, for a 10 microL injection volume. The percentage recovery of exo-isomer ranged from 99 to 102% w/w in the endo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine sample. The test solution and mobile phase were observed to be stable up to 48 h after preparation. The validated method yielded good results for precision, linearity, accuracy, robustness and ruggedness. The proposed method was found to be suitable and accurate for the quantitative determination of exo-isomer in bulk samples of endo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine.